Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEPHANIE V BLANK

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecologic Oncology

NPI
1043211626
CMS profile
46868
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$37.23

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $37.23 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $37.23 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEPHANIE V BLANK

NPI 1043211626 · CMS profile ID 46868

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Gynecologic Oncology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043211626?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEPHANIE V BLANK, NPI 1043211626, CMS profile ID 46868. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043211626?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). STEPHANIE V BLANK, NPI 1043211626, CMS profile ID 46868. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043211626?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
STEPHANIE V BLANK, NPI 1043211626, CMS profile ID 46868, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1043211626?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $37.23 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $37.2309/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944868715 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $23.98 2
PY2021 $86.27 2
PY2022 $37.23 1
PY2025 $153.17 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $226,900.10 37
PY2024 Principal investigator $170,088.03 42
PY2023 Principal investigator $268,544.71 34
PY2022 Principal investigator $532,628.40 36
PY2021 Recipient $460.98 2
PY2021 Principal investigator $559,085.02 64
PY2020 Principal investigator $916,005.72 160
PY2019 Principal investigator $645,377.42 103

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

66 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $3,410.05 12/31/2021 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 848749103
Principal investigator 1 Merck Sharp & Dohme Corporation $97,720.55 12/31/2021 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 848749105
Principal investigator 1 Merck Sharp & Dohme Corporation $10,705.93 12/31/2021 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 848755643
Principal investigator 1 Merck Sharp & Dohme Corporation $70,686.34 12/31/2021 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 848755645
Principal investigator 1 Merck Sharp & Dohme Corporation $78,152.60 12/22/2021 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 848755607
Principal investigator 1 Seagen Inc. $550.00 12/22/2021 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 792656821
Principal investigator 1 Merck Sharp & Dohme Corporation $76,150.70 12/17/2021 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 848749065
Principal investigator 1 GlaxoSmithKline, LLC. $5,907.60 12/14/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809540905
Principal investigator 1 GlaxoSmithKline, LLC. $2,025.00 12/14/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809541469
Principal investigator 1 Genentech, Inc. $13,000.00 12/13/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 835942141
Principal investigator 1 GlaxoSmithKline, LLC. $950.00 11/30/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809525877
Principal investigator 1 GlaxoSmithKline, LLC. $5,568.30 11/23/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809540899
Principal investigator 1 Seagen Inc. $895.00 11/17/2021 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 792656819
Principal investigator 1 GlaxoSmithKline, LLC. $1,934.10 10/26/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809503583
Principal investigator 1 Seagen Inc. $631.80 10/20/2021 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 792656825
Principal investigator 1 Seagen Inc. $2,025.00 10/13/2021 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 792656823
Principal investigator 1 GlaxoSmithKline, LLC. $10,228.50 09/14/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809540893
Principal investigator 1 Genentech, Inc. $841.00 09/01/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 835942135
Principal investigator 1 Genentech, Inc. $750.00 08/27/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 835942119
Principal investigator 1 Genentech, Inc. $845.00 08/27/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 835942125
Principal investigator 1 Genentech, Inc. $3,304.00 08/27/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 835942129
Principal investigator 1 Seagen Inc. $895.00 08/25/2021 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 792656809
Principal investigator 1 Genentech, Inc. $3,342.62 08/18/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 835942113
Principal investigator 1 Seagen Inc. $1,108.79 08/18/2021 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 792656815
Principal investigator 1 GlaxoSmithKline, LLC. $554.00 08/17/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809505029
Principal investigator 1 Genentech, Inc. $1,962.50 08/11/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
GLOBAL RANDOMIZED PHASE II STUDY WITH REGISTRATIONAL POTENTIAL IN 2L PD L1 CERVICAL CANCER No dispute reported 06/30/2026 835942433
Principal investigator 1 Seagen Inc. $2,025.00 08/11/2021 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 792656811
Principal investigator 1 GlaxoSmithKline, LLC. $2,363.00 08/10/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809504981
Principal investigator 1 Seagen Inc. $2,025.00 07/14/2021 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 792656813
Principal investigator 1 GlaxoSmithKline, LLC. $2,893.50 07/13/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809496439
Principal investigator 1 Genentech, Inc. $3,342.62 07/01/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 835942107
Principal investigator 1 GlaxoSmithKline, LLC. $12,519.00 06/29/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809481561
Principal investigator 1 GlaxoSmithKline, LLC. $338.00 06/29/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809481981
Principal investigator 1 Seagen Inc. $364.50 06/23/2021 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 792656789
Principal investigator 1 Seagen Inc. $1,215.00 06/23/2021 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 792656791
Principal investigator 1 Seagen Inc. $35,934.30 06/16/2021 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 792656795
Principal investigator 1 Genentech, Inc. $845.00 06/02/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 835942101
Principal investigator 1 GlaxoSmithKline, LLC. $3,039.00 06/02/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809481979
Principal investigator 1 Genentech, Inc. $7,325.00 05/19/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
GLOBAL RANDOMIZED PHASE II STUDY WITH REGISTRATIONAL POTENTIAL IN 2L PD L1 CERVICAL CANCER No dispute reported 06/30/2026 835942381
Principal investigator 1 GlaxoSmithKline, LLC. $2,420.10 05/04/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809480121
Principal investigator 1 Seagen Inc. $2,193.75 04/28/2021 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 792656785
Principal investigator 1 Seagen Inc. $364.50 04/28/2021 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 792656787
Principal investigator 1 Genentech, Inc. $950.00 04/21/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
GLOBAL RANDOMIZED PHASE II STUDY WITH REGISTRATIONAL POTENTIAL IN 2L PD L1 CERVICAL CANCER No dispute reported 06/30/2026 835942369
Principal investigator 1 GlaxoSmithKline, LLC. $3,560.40 04/20/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809479959
Principal investigator 1 GlaxoSmithKline, LLC. $7,912.00 04/20/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809480555
Principal investigator 1 Seagen Inc. $1,925.00 04/14/2021 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 792656781
Principal investigator 1 Seagen Inc. $1,282.50 04/07/2021 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 792656783
Principal investigator 1 Seagen Inc. $5,408.10 04/07/2021 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 792656793
Recipient F. Hoffmann-La Roche AG $206.85 03/31/2021 Covered Recipient Physician A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER No dispute reported 06/30/2026 835904609
Recipient F. Hoffmann-La Roche AG $254.13 03/31/2021 Covered Recipient Physician A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER No dispute reported 06/30/2026 835904615
Principal investigator 1 Genentech, Inc. $1,682.00 03/24/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 835942083
Principal investigator 1 Genentech, Inc. $3,364.00 03/24/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 835942089
Principal investigator 1 Genentech, Inc. $3,342.62 03/24/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 835942095
Principal investigator 1 Seagen Inc. $337.50 03/24/2021 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 792656771
Principal investigator 1 Genentech, Inc. $950.00 03/22/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
GLOBAL RANDOMIZED PHASE II STUDY WITH REGISTRATIONAL POTENTIAL IN 2L PD L1 CERVICAL CANCER No dispute reported 06/30/2026 835942345
Principal investigator 1 GlaxoSmithKline, LLC. $5,314.00 03/16/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809479931
Principal investigator 1 GlaxoSmithKline, LLC. $2,221.00 02/23/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809483603
Principal investigator 1 Genentech, Inc. $2,583.00 02/17/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 835942077
Principal investigator 1 GlaxoSmithKline, LLC. $15,593.40 02/17/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809482663
Principal investigator 1 Seagen Inc. $3,225.15 02/03/2021 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 792656779
Principal investigator 1 Seagen Inc. $11,812.50 01/27/2021 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 792656773
Principal investigator 1 Seagen Inc. $364.50 01/27/2021 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 792656775
Principal investigator 1 Seagen Inc. $945.00 01/27/2021 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 792656777
Principal investigator 1 GlaxoSmithKline, LLC. $11,813.00 01/26/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809478123
Principal investigator 1 Genentech, Inc. $1,075.00 01/20/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
GLOBAL RANDOMIZED PHASE II STUDY WITH REGISTRATIONAL POTENTIAL IN 2L PD L1 CERVICAL CANCER No dispute reported 06/30/2026 835942333
Principal investigator 1 GlaxoSmithKline, LLC. $72.70 01/12/2021 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809478013